IDiyas

For the Inventor, By the Inventor

Mystic, CT, United States of America

Willard McKowan Welch, Jr

USPTO Granted Patents = 15

Average Co-Inventor Count = 2.1

ph-index = 7

Forward Citations = 109(Granted Patents)


Location History:

  • New London, CT (US) (1995)
  • Mystic, CT (US) (1998 - 2007)

Company Filing History:

goldMedal14 out of 4,455 
 
Pfizer Corporation
 patents
silverMedal1 out of 1 
 
Pflizer Inc.
 patent

Years Active: 1995-2007

Loading Chart...
15 patents (USPTO):Explore Patents
1. 7241798 - NK1 antagonists (2007-07-10),
2. 7067555 - Sertraline oral concentrate (2006-06-27),
3. 7009051 - 4-(2-pyridyl) piperazines having 5HT7 receptor agonist activity (2006-03-07),
4. 6921764 - Thieno-pyrimidin-4-one AMPA antagonists (2005-07-26),
5. 6727283 - Sertraline oral concentrate (2004-04-27),
6. 6627755 - Quinazolin-4-one AMPA antagonists (2003-09-30),
7. 6448265 - Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity (2002-09-10),
8. 6441018 - Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity (2002-08-27),
9. 6380204 - Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions (2002-04-30),
10. 6306864 - Atropisomers of 3-aryl-4(3H)-quinazolinones and their use as AMPA-receptor antagonists (2001-10-23),
11. 6255322 - 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents (2001-07-03),
12. 6103900 - Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity (2000-08-15),
13. 6005109 - Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity (1999-12-21),
14. 5712303 - Pyrazoles and pyrazolopyrimidines having CRF antagonistic activity (1998-01-27),
15. 5442116 - Process for preparing sertraline intermediates (1995-08-15),

Title: The Innovations of Willard McKowan Welch, Jr.

Introduction

Willard McKowan Welch, Jr. is a prominent inventor based in Mystic, CT, known for his significant contributions to pharmaceutical sciences. With an impressive portfolio of 15 patents, Welch has made strides in developing innovative pharmaceutical compositions and methods of treatment for various conditions.

Latest Patents

Among his latest inventions are two notable patents: first, the development of NK1 antagonists, which are compounds that exhibit neurokinin inhibitory properties. This invention includes pharmaceutical compositions and methods of treatment aimed at neurokinin-mediated conditions. Second, he has created a sertraline oral concentrate, a nonaqueous liquid composition designed for oral administration that contains sertraline or its pharmaceutically acceptable salts. This patent outlines a method for utilizing the concentrate to treat or prevent various diseases, offering a novel approach to medication delivery.

Career Highlights

Willard McKowan Welch, Jr. has had a fruitful career, having worked with renowned companies in the pharmaceutical sector, including Pfizer Corporation and Pfizer Inc. His experience at these firms has significantly influenced his ability to innovate and refine pharmaceutical technologies.

Collaborations

Throughout his career, Welch has collaborated with esteemed professionals, including William Stephen Faraci and Bertrand Leo Chenard. These partnerships have enabled him to enhance his research and development efforts, further amplifying his impact in the field.

Conclusion

Willard McKowan Welch, Jr. exemplifies the spirit of innovation in pharmaceuticals through his numerous patents and collaborations. His work not only advances scientific understanding but also provides practical solutions for treating complex medical conditions, showcasing the vital role of inventors in improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…